Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trialJ. Guigay, Franck Darloy, Cédrik Lafond et al.|The Lancet Oncology|2021Cited by 231
Avapritinib versus Placebo in Indolent Systemic MastocytosisJason Gotlib, Robyn M. Scherber, Mariana Castells et al.|NEJM Evidence|2023Cited by 74